On Thursday, AbbVie Inc. (ABBV) announced that the Canadian Headache Society's revised Migraine Prevention Guideline has strongly endorsed the use of Atogepant for treating both episodic and chronic migraines, as well as OnabotulinumtoxinA specifically for chronic migraines. These endorsements are grounded in data highlighting the potential benefits of these medications, according to the company. In pre-market trading, AbbVie shares are listed at $173 on the New York Stock Exchange, reflecting a marginal decline of 0.01 percent.
The material has been provided by InstaForex Company - www.instaforex.com
The material has been provided by InstaForex Company - www.instaforex.com